These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 28208525)

  • 1. Re: Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve?
    Penson DF
    J Urol; 2017 Mar; 197(3 Pt 1):703. PubMed ID: 28208525
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Villers A; Olivier J
    Eur Urol; 2018 Sep; 74(3):396. PubMed ID: 29650234
    [No Abstract]   [Full Text] [Related]  

  • 3. Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance.
    Koo KC; Park SU; Rha KH; Hong SJ; Yang SC; Hong CH; Chung BH
    Jpn J Clin Oncol; 2015 Aug; 45(8):785-90. PubMed ID: 25979243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
    Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
    J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
    Taneja SS
    J Urol; 2015 Jan; 193(1):128-9. PubMed ID: 25523659
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Risk Group and Death from Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-Risk Prostate Cancer.
    Taneja SS
    J Urol; 2016 Aug; 196(2):412-3. PubMed ID: 27479379
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Active Surveillance in Younger Men with Prostate Cancer.
    Özen H; Türkeri LN
    Eur Urol; 2018 May; 73(5):807. PubMed ID: 29273409
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Role of the 4Kscore Test as a Predictor of Reclassification in Prostate Cancer Active Surveillance.
    Taneja SS
    J Urol; 2019 Feb; 201(2):228. PubMed ID: 30634339
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Quantified Clinical Risk Change as an End Point during Prostate Cancer Active Surveillance.
    Taneja SS
    J Urol; 2017 Mar; 197(3 Pt 1):699-700. PubMed ID: 28208519
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.
    Penson DF
    J Urol; 2017 Jan; 197(1):153-154. PubMed ID: 27979510
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Active Surveillance in Younger Men with Prostate Cancer.
    Taneja SS
    J Urol; 2017 Oct; 198(4):741-745. PubMed ID: 28905784
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Long-term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer.
    Nyame YA; Stephenson AJ; Klein E
    Eur Urol; 2015 Nov; 68(5):906-7. PubMed ID: 26460873
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Long-term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer.
    Loeb S
    Eur Urol; 2015 Nov; 68(5):907. PubMed ID: 26460874
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
    van den Bergh RC; Zargar H; Murphy DG
    Eur Urol; 2016 May; 69(5):964-5. PubMed ID: 27301991
    [No Abstract]   [Full Text] [Related]  

  • 15. Aligning evidence and practice: future research needs to increase utilization of active surveillance for favorable risk prostate cancer.
    Carter HB
    Curr Opin Urol; 2015 May; 25(3):277-82. PubMed ID: 25692722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Kryvenko et al.: Prostate-specific Antigen Mass Density - A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution (Urology, 2016;90:141-147).
    Pishgar F
    Urology; 2016 Apr; 90():228-9. PubMed ID: 26809070
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.
    Shah N; Ioffe V
    J Urol; 2019 Oct; 202(4):821. PubMed ID: 31163008
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Kallidonis P; Liatsikos E
    Eur Urol; 2017 May; 71(5):833. PubMed ID: 28104313
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
    Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
    Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
    Whitson JM; Porten SP; Hilton JF; Cowan JE; Perez N; Cooperberg MR; Greene KL; Meng MV; Simko JP; Shinohara K; Carroll PR
    J Urol; 2011 May; 185(5):1656-60. PubMed ID: 21419438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.